Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size

• The Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size was valued at USD 473.59 Million in 2024 and is expected to reach USD 743.53 Million by 2032, at a CAGR of 5.8% during the forecast period
• The market growth is largely fueled by increasing awareness of exocrine pancreatic insufficiency (EPI) among healthcare professionals and patients, coupled with the rising prevalence of chronic pancreatic disorders, which is driving demand for advanced therapeutic and diagnostic solutions
• Furthermore, advancements in enzyme replacement therapies, diagnostic kits, and patient-friendly formulations are enabling better management of EPI, improving clinical outcomes and patient quality of life. These converging factors are accelerating the uptake of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics solutions, thereby significantly boosting the industry's growth

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Analysis

• The Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is witnessing substantial growth, driven by increasing healthcare investments, rising awareness of gastrointestinal disorders, and the adoption of advanced diagnostic and therapeutic technologies
• The escalating demand for EPI therapeutics and diagnostics is primarily fueled by the prevalence of chronic pancreatitis, cystic fibrosis, and other conditions causing pancreatic insufficiency, coupled with rising diagnosis rates and growing government healthcare initiatives across the region
• Saudi Arabia dominated the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market with the largest revenue share of 37.85% in 2024, supported by strong government healthcare initiatives, the expansion of specialized neurology and gastroenterology centers, and significant investments in digital health infrastructure. Collaborations between global medical device manufacturers and leading Saudi hospitals have accelerated adoption by ensuring access to advanced diagnostic tools and specialized training programs
• The United Arab Emirates is expected to be the fastest-growing country in the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market during the forecast period, registering a CAGR of 11.00% from 2025 to 2032, driven by rising healthcare spending, expansion of smart hospitals, increasing prevalence of gastrointestinal disorders, and government-led initiatives to integrate advanced healthcare technologies and telemedicine platforms
• The PERT segment dominated with a Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share of 61.3% in 2024, as it is the cornerstone therapy for managing EPI and restoring digestive function

Report Scope and Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segmentation         

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Trends

Growing Adoption of Advanced Diagnostic and Therapeutic Solutions

• A significant and accelerating trend in the Middle East and Africa exocrine pancreatic insufficiency (EPI) Therapeutics and Diagnostics market is the increasing adoption of advanced diagnostic tools and therapeutic solutions, including wearable monitoring devices, smart diagnostic platforms, and cloud-enabled patient management systems. These technologies are improving disease detection, enabling timely intervention, and enhancing patient outcomes
  • For instance, leading medical centers in Saudi Arabia and the UAE have begun implementing integrated EPI monitoring systems that combine continuous biochemical testing with digital health platforms, allowing clinicians to track pancreatic enzyme levels and nutritional status remotely, while providing personalized treatment recommendations
• Healthcare providers are increasingly leveraging telemedicine-enabled EPI monitoring solutions to manage patients in both hospital and homecare settings, particularly in regions with limited access to specialized gastroenterology centers. These platforms facilitate real-time patient data collection, automated reporting, and secure cloud-based storage of sensitive medical records
• The seamless integration of wearable and smart diagnostic tools with hospital information systems allows for centralized monitoring of multiple patients, supporting efficient resource allocation, reducing hospital visits, and minimizing delays in treatment
• This trend toward advanced, connected, and patient-centric diagnostic and therapeutic systems is reshaping the approach to EPI care in the Middle East and Africa. Companies such as Natus Medical and Masimo are collaborating with regional healthcare institutions to implement next-generation EPI monitoring technologies, ensuring rapid adoption of innovative solutions
• The demand for comprehensive EPI therapeutics and diagnostics is growing rapidly across both hospital and homecare sectors, as healthcare providers aim to improve patient management, reduce complications, and enhance overall quality of care in the region

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics

Driver

Growing Need Due to Rising Prevalence of EPI and Awareness Among Healthcare Providers

• The rising incidence of exocrine pancreatic insufficiency (EPI) across the Middle East and Africa, coupled with increased awareness among healthcare professionals and patients, is a major driver of market growth. Early diagnosis and effective treatment options are becoming a priority in both pediatric and adult patient populations
  • For instance, A 2021 study at Benha University, Egypt found over 30% of diabetic patients had exocrine pancreatic insufficiency, highlighting rising incidence and the need for early diagnosis and treatment in the region
• Healthcare providers are increasingly adopting Pancreatic Enzyme Replacement Therapy (PERT) and nutritional management solutions to improve patient outcomes, leading to steady demand for both branded and generic therapeutics
• Moreover, growing awareness about the importance of pancreatic function testing and imaging diagnostics is making EPI diagnostic solutions a critical component of gastrointestinal care. Hospitals, specialty clinics, and homecare providers are adopting comprehensive EPI management strategies to monitor and treat patients effectively
• The availability of advanced diagnostic tools and therapies that enable personalized treatment plans is further propelling market growth. Patients benefit from improved quality of life through early detection, accurate monitoring, and tailored therapy regimens

Restraint/Challenge

Concerns Regarding High Costs and Limited Accessibility

• Despite market growth, high costs associated with advanced diagnostic tests, enzyme therapies, and nutritional management solutions remain a significant barrier, particularly in price-sensitive regions of the Middle East and Africa. This limits widespread adoption in rural areas and among low-income populations
• Access to specialized diagnostic facilities is still uneven across the region, with certain countries lacking the infrastructure to perform pancreatic function tests or advanced imaging studies, which can hinder early detection and timely therapy
• Reimbursement and insurance coverage variations further complicate access, as some patients may have to bear out-of-pocket expenses for diagnostics and therapies, affecting overall market penetration
• Addressing these challenges requires strategic interventions such as expanding generic therapy availability, lowering the cost of diagnostics, and improving distribution networks to reach under-served regions
• Education initiatives for healthcare providers and patients regarding the importance of early diagnosis, proper enzyme dosing, and nutritional management are also critical to overcome adoption barriers
• Overcoming these constraints through government support, partnerships with local healthcare providers, and patient assistance programs will be pivotal in ensuring sustainable market growth and improving access to quality EPI care across the Middle East and Africa

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Scope

The market is segmented on the basis of diagnosis, treatment, drug type, end user, and distribution channel.

• By Diagnosis

On the basis of diagnosis, the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into imaging tests and pancreatic function tests. The imaging tests segment dominated with a market share of 55.4% in 2024, driven by its ability to provide highly accurate visualization of the pancreas and detect structural abnormalities. Hospitals and specialty clinics in Saudi Arabia rely on advanced modalities such as MRI, CT scans, and endoscopic ultrasound for early and precise diagnosis. The segment’s dominance is supported by well-established diagnostic centers, high patient inflow, and government investment in imaging infrastructure. Imaging tests are crucial for both adult and pediatric populations, providing reliable baseline data for treatment planning. Strong partnerships between technology providers and hospitals further reinforce adoption. The segment’s high diagnostic accuracy, non-invasive nature, and rapid reporting make it the preferred choice in major healthcare facilities.

The pancreatic function tests segment is expected to witness the fastest CAGR of 12.1% from 2025 to 2032, fueled by increasing awareness about EPI in both pediatric and adult populations. These tests, such as fecal elastase measurement and direct pancreatic function tests, help confirm enzyme insufficiency, guide enzyme replacement therapy, and monitor disease progression. Expanding healthcare coverage, government initiatives to enhance gastrointestinal diagnostics, and rising patient demand in the UAE and other emerging markets drive rapid growth. The adoption of minimally invasive and home-based testing solutions further accelerates market penetration.

• By Treatment

On the basis of treatment, the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into nutritional management and pancreatic enzyme replacement therapy (PERT). The PERT segment dominated with a market share of 61.3% in 2024, as it is the cornerstone therapy for managing EPI and restoring digestive function. Hospitals, specialty clinics, and homecare providers in Saudi Arabia and UAE increasingly rely on PERT to improve nutrient absorption and alleviate gastrointestinal symptoms. The segment benefits from robust clinical evidence supporting its efficacy and safety, alongside widespread availability and physician preference. Continuous medical training programs, awareness campaigns, and collaborations with global pharmaceutical companies reinforce dominance. PERT’s ability to provide personalized dosing for different age groups and disease severities strengthens its adoption. The therapy’s integration into standardized EPI care pathways ensures consistent patient outcomes.

The nutritional management segment is expected to witness the fastest CAGR of 11.5% from 2025 to 2032, driven by the growing focus on dietary interventions as a complement to enzyme therapy. Increasing malnutrition concerns among EPI patients and heightened awareness of nutrition’s role in improving quality of life support growth. Expansion of homecare and outpatient nutrition services, along with educational programs for patients and caregivers, enhances adoption. The availability of specialized nutritional supplements and fortified foods in the region further fuels market development.

• By Drug Type

On the basis of drug type, the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into generic and branded formulations. The branded segment dominated with a market share of 58.7% in 2024, attributed to its established clinical reliability, strong physician preference, and patient trust. Branded therapies are widely available in Saudi Arabia and UAE through hospital supply chains and authorized distributors, ensuring quality, consistency, and adherence to clinical guidelines. Partnerships between global pharmaceutical companies and regional distributors facilitate smooth supply and specialized training. The segment’s leadership is further reinforced by marketing campaigns, clinical endorsements, and post-market support. Physicians often recommend branded PERT for its standardized potency and predictable patient outcomes, especially for chronic and severe EPI cases.

The generic segment is expected to witness the fastest CAGR of 10.8% from 2025 to 2032, driven by increasing affordability and accessibility in emerging healthcare markets across the Middle East and Africa. Rising government initiatives and policies aimed at promoting cost-effective therapies are supporting broader adoption among patients who are price-sensitive. Growing awareness of generic options and their comparable efficacy to branded therapies is encouraging uptake in hospitals, specialty clinics, and homecare settings. The expansion of regional and international generic manufacturing facilities ensures a steady supply of high-quality products, further fueling market growth. In addition, generic drugs are becoming increasingly popular in smaller clinics and community healthcare centers, enabling wider access to essential Exocrine Pancreatic Insufficiency (EPI) treatments. Healthcare providers are leveraging generic formulations to optimize treatment costs without compromising clinical outcomes. The combined impact of regulatory support, market accessibility, and patient acceptance is propelling the generic segment as the fastest-growing subsegment in the region.

• By End User

On the basis of end user, the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, and others. The hospitals segment dominated with a market share of 64.2% in 2024, owing to advanced infrastructure, high patient volumes, and centralized availability of both diagnostic and therapeutic services. Hospitals in Saudi Arabia and UAE provide comprehensive EPI care, combining imaging, PERT, and nutritional support under one roof. This centralized approach ensures accurate diagnosis, proper dosing, and continuous monitoring of patients. Well-established tertiary hospitals and government investments in specialized centers reinforce dominance. Hospitals also serve as referral hubs for complex cases, further consolidating their market share.

The homecare segment is expected to witness the fastest CAGR of 13.2% from 2025 to 2032, driven by growing awareness among patients and caregivers regarding effective management of Exocrine Pancreatic Insufficiency (EPI) outside hospital settings. Advances in remote patient monitoring, at-home pancreatic enzyme therapy kits, and portable diagnostic tools are significantly enhancing treatment accessibility. The expansion of homecare services across the Middle East and Africa, coupled with the rising prevalence of chronic EPI cases, is fueling demand for convenient, patient-centered care solutions. Patients increasingly prefer home-based treatments due to reduced travel, personalized care, and improved comfort. In addition, government initiatives promoting outpatient care, insurance coverage for home treatments, and partnerships with healthcare providers are further accelerating adoption. The growing infrastructure for home-based healthcare, combined with technological innovations, is positioning the homecare segment as the fastest-growing subsegment in the regional EPI therapeutics and diagnostics market.

• By Distribution Channel

On the basis of distribution channel, the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into direct tender, retail pharmacy, third-party distributors, and others. The direct tender segment dominated with a market share of 59.8% in 2024, supported by government procurement programs, hospital contracts, and bulk supply agreements for diagnostic equipment and PERT therapies. Large-scale tenders in Saudi Arabia and UAE ensure timely access to high-quality EPI products in both public and private hospitals. Strong collaborations between suppliers and healthcare institutions streamline logistics, training, and post-sale support. Government-led programs for centralized procurement further reinforce dominance, ensuring affordability and consistent supply.

The retail pharmacy segment is expected to witness the fastest CAGR of 11.4% from 2025 to 2032, fueled by expanding patient access to pancreatic enzyme replacement therapy (PERT), nutritional supplements, and homecare products. The growth is supported by the rapid expansion of pharmacy networks across Middle Eastern and African countries, improving the availability of essential therapies for EPI patients. Increasing awareness among patients and caregivers regarding the importance of consistent treatment and early intervention is further driving demand. Retail pharmacies also play a critical role in patient education, providing guidance on dosage, dietary management, and therapy adherence. The ease of access to over-the-counter solutions, coupled with the convenience of frequent purchases and proximity to patients’ homes, strengthens the adoption of retail channels. In addition, retail pharmacies facilitate repeat purchases and reinforce treatment compliance, making them a vital and rapidly expanding distribution route in the regional EPI therapeutics and diagnostics market.

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Regional Analysis

• The Middle East & Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is witnessing steady growth
• Driven by increasing healthcare investments, rising prevalence of gastrointestinal disorders, and the expansion of specialized diagnostic and therapeutic facilities
• The region’s focus on enhancing healthcare infrastructure, digital health adoption, and patient-centric services is further boosting the demand for advanced EPI diagnostics and therapeutics

Saudi Arabia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Insight

The Saudi Arabia exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market dominated the Middle East & Africa EPI therapeutics and diagnostics market with the largest revenue share of 37.85% in 2024. The market growth is supported by robust government healthcare initiatives, expansion of specialized neurology and gastroenterology centers, and significant investments in digital health infrastructure. Partnerships between leading hospitals and global medical device manufacturers have facilitated access to advanced diagnostic solutions and specialized training programs. In addition, rising awareness among healthcare professionals and patients regarding early detection and management of EPI is driving higher adoption of therapeutic and diagnostic solutions.

U.A.E Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Insight

The UAE exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to be the fastest-growing country in the Middle East & Africa EPI therapeutics and diagnostics market during the forecast period, registering a CAGR of 11.00% from 2025 to 2032. Growth is fueled by increasing healthcare expenditure, expansion of smart hospitals and specialized clinics, and rising prevalence of gastrointestinal disorders. Government-led initiatives promoting advanced healthcare technologies, telemedicine platforms, and integrated patient care models are further accelerating adoption. The UAE’s proactive investment in healthcare infrastructure ensures broader accessibility of EPI diagnostics and therapeutics, especially in urban centers and rapidly developing regions.

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share

The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics industry is primarily led by well-established companies, including:

• EagleBio (U.S.)
• AbbVie (U.S.)
• Nordmark Arzneimittel GmbH & Co. (Germany)
• Digestive Care, Inc. (U.S.)
• Alcresta Therapeutics, Inc. (U.S.)
• ChiRhoClin (U.S.)
• Abbott (U.S.)
• Bioserv Diagnostics (Germany)
• Labcorp (U.S.)
• Organon group of companies (Netherlands)
• Metagenics LLC (U.S.)
• Johnson & Johnson and its affiliates (U.S.)
• Nestlé (Switzerland)

Latest Developments in Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

• In August 2025, AzurRx Biopharma announced positive Phase 2 clinical trial results for its Exocrine Pancreatic Insufficiency (EPI) treatment candidate, highlighting significant improvements in digestive enzyme activity and symptom management. This advancement is expected to enhance therapeutic options for EPI patients across the Middle East and Africa, providing clinicians with more effective treatment protocols
• In 2021, AbbVie launched a new formulation of its enzyme replacement therapy (ERT) product specifically aimed at EPI patients in the Middle East and Africa. The reformulated therapy improves patient compliance and efficacy, supporting better management of digestive complications associated with EPI and reinforcing AbbVie’s commitment to expanding treatment accessibility in emerging markets

SKU-70030